Navigation Links
Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
Date:9/20/2010

In an effort to tap into the vast potential of the oceans as a source for novel medical treatments, the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense (DoD), has awarded San Diego-based Trius Therapeutics, Inc. a four-and-a-half year contract worth up to $29.5 million to collaborate with Scripps Institution of Oceanography at UC San Diego for the development of novel antibiotics directed against microorganisms that cause serious infections.

Trius will use its proprietary Focused Antisense Screening Technology (FAST) to identify the targets of antibacterial compounds from marine natural product libraries discovered by William Fenical, Distinguished Professor of Oceanography at Scripps Institution of Oceanography and Director of Scripps' Center for Marine Biotechnology and Biomedicine.

A pioneer in the field of marine biomedicine, Fenical has led efforts to explore the oceans in search of novel microbial sources that can lead to the development of new cures for a variety of diseases. Expeditions to Fiji, the Bahamas, and just off the Scripps Pier, to name a few destinations, have yielded promising drug compounds to treat cancer and other illnesses. The oceans, which remain largely unexplored, offer a broad diversity of environments that Fenical and his colleagues are examining for novel organisms and unique chemical structures.

Under the new DTRA award, Trius will apply its structure-based drug design capabilities to optimize antibacterial compounds for activity against biodefense pathogens such as Yersinia pestis, Francisella tularensis and Burkholderia pseudomallei. Trius believes that these compounds also will be active against drug-resistant pathogens involved in hospital-acquired infections.

"We are now facing an epidemic because drug resistance is growing at an alarming rate," said Fenical. "The oceans are a huge resource where biodiversity is greatest on our planet. The biomedical potential comes from plants, animals and microbes that have unique genetic compositions."

"The underlying objective is to identify new compounds for treating infections caused by pathogens that can be used as bioweapons," said Jeffrey Stein, chief executive officer of Trius and a Scripps Oceanography alumnus. "New antimicrobial compounds and mechanisms of action are likely to have a commercial benefit as well, in an age where bacterial pathogens are acquiring resistance to existing antibiotics in both the hospital and in the community."

Stein added, "William Fenical and his team at Scripps offer a unique resource in tapping marine microorganisms for the discovery of powerful new antibiotics to address these needs. We are marrying the natural product research resources at Scripps with Trius' expertise in target discovery and structure-based medicinal chemistry in an effort to identify molecules with high potential for product development. Together with Scripps, Trius is leveraging billions of years of evolution inherent in natural products with the most advanced tools in drug design and optimization."


'/>"/>

Contact: Mario Aguilera
scrippsnews@ucsd.edu
858-534-3624
University of California -- San Diego
Source:Eurekalert  

Related medicine news :

1. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
2. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
3. Scripps Blood & Marrow Transplant Program Celebrates 30th Anniversary of Providing Life-Saving Care
4. Scripps Memorial Hospital La Jolla First in San Diego to Achieve Magnet Nursing Re-designation
5. Scripps Announces Plans for Region's First Proton Therapy Center; $185 Million Facility to Offer Advanced Care to Cancer Patients
6. Scripps Research scientists share $2 million in Florida state research grants
7. Scripps Center for Executive Health Now Offers Genetic Testing
8. Scripps Research scientists uncover previously unknown natural mechanism that controls cocaine use
9. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
10. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
11. Cochlear Appoints Switched on Media to Develop its SEO Across the Asia Pacific Region
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: